Aptose Biosciences (TSE:APS) has released an update.
Aptose Biosciences Inc., a precision oncology company, is set to announce its first-quarter financial results and provide a clinical strategy update on May 14, 2024, focusing on the advancement of its lead drug candidate, tuspetinib. The announcement will include a review by the company’s Chief Medical Officer, Dr. Rafael Bejar, on a triplet drug combination for treating newly diagnosed acute myeloid leukemia (AML) patients. The event will be accessible via webcast, with a replay available on the Aptose website for 30 days.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
